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The prevalence of vision-threatening diseases of the posterior eye segment, such as age-
related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema and 
glaucoma, is increasing worldwide. This is a major burden to patients and health care 
systems. Current therapy includes intravitreal injections of anti-angiogenic agents against 
vascular endothelial growth factor (VEGF), because drug delivery to the back of the eye is 
hampered by anatomical and physiological barriers. Intravitreal injections are 
uncomfortable, may cause adverse reactions and reduced compliance leading to suboptimal 
treatment outcomes. Furthermore, current anti-VEGF drugs are not effective in all patients. 
Therefore, new drugs and delivery systems for targeted and prolonged action are needed 
for posterior segment eye treatment. Nanoparticles have been investigated as a long-acting 
and targeted ocular drug delivery systems that may prolong actions of small molecule 
drugs (e.g. corticosteroids and tyrosine kinase inhibitors) with short vitreal half-lives. 
Nanoparticles are also important for delivery of labile therapeutics with intracellular 
targets, including some proteins, neuroprotective peptides and nucleic acids (RNA, DNA). 
However, several barriers hamper retinal delivery of intravitreal nanoparticles and 
interspecies differences may lead to poor clinical translation. Hence, the overall objective 
of this study was to generate improved understanding of ocular barriers to retinal delivery 
of nanoparticles by using translationally valid preclinical models. We systematically 
studied vitreal diffusion of various liposomes and other lipid-based nanoparticles by 
analyzing the mobility of the nanoparticles with single particle tracking in intact porcine 
central vitreous with similar structure to human vitreous. We evaluated the 
physicochemical features of nanoparticles affecting their vitreal mobility (e.g. particle size, 
surface change, surface coating with polyethylene glycol or hyaluronic acid). Neutral and 
anionic liposomes showed faster diffusion than cationic liposomes. Small size and polymer 
coating modestly facilitated vitreal mobility of liposomes. Kinetic analysis demonstrated 
that nanoparticles’ distribution in the human vitreous is controlled by convection rather 
than diffusion, while vitreous liquefaction may increase the role of nanoparticle diffusion. 
We also studied protein corona formation on liposomes’ surface, since it may affect the 
hydrodynamic diameter and cellular interactions. In this regard, surface plasmon resonance 
analysis was performed to monitor the protein corona formation in the presence of porcine 
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vitreous. Insignificant size change was seen indicating that vitreal diffusion is not 
influenced by protein corona. In addition, high-resolution proteomics confirmed identity of 
the proteins on liposomal surface that may change the biological interactions of the 
liposomes. Next, retinal permeation of liposomes was studied systematically using ex vivo 
analyses and bovine retinal explants. Neutral and anionic liposomes with high vitreal 
mobility were studied for their potential in overcoming the ILM barrier. Liposomes with 
diameters over 100 nm fail in retinal entry irrespective of their surface charge, while small 
anionic PEG-coated liposomes (<50 nm) distributed into the retina. Lastly, a liposomal 
formulation was developed to encapsulate sunitinib, a small molecule anti-neovascular 
drug for VEGF suppression. Unlike sunitinib solution, the liposomal formulation showed 
anti-neovascular effect in laser induced mouse choroidal neovascularization model. In 
summary, this study extended understanding of the retinal drug delivery barriers related to 
the intravitreal injections. It also informed about the role of nanoparticles’ characteristics 
on their interactions with ocular barriers. These findings can be leveraged in understanding 
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1   INTRODUCTION
Vision is considered as the most important of our senses being vital for independent 
connections with the world. Given its fundamental role in our life, the loss of vision has a 
huge negative impact on the quality of life. Currently, 2.2 billion people suffer from some 
vision impairment; among them tens of millions of patients have severe vision-threatening 
conditions affecting the back of the eye (World report on vision, WHO, 2019). Aging is the 
primary factor associated with many of retinal diseases, such as glaucoma, age-related 
macular degeneration (AMD) and diabetic retinopathy (DR). Considering the current 
population growth, the number of patients with such diseases will sharply increase in the 
coming years, particularly in industrialized countries. This situation requires development 
of effective treatments to many diseases. Currently, intravitreally injected anti-VEGF 
therapeutics are the most important treatments for AMD and DR [1,2].
Despite significant medical progress during the last two decades, retinal therapy remains 
challenging because various barriers hinder the delivery of therapeutic agents to the target 
sites in the retina and choroid [3]. Therefore, topical and systemic routes of administration 
are not clinically viable options for retinal treatments, since less than 0.001% of applied 
dose reaches the retina after topical installation of eye drops [4]. For this reason, retina is 
typically treated using direct intravitreal injections of drugs, for example anti-VEGF 
biologics, to achieve therapeutic drug levels in the retina and choroid [5]. Injections must 
be given by specialized nurse or ophthalmologist, often at monthly intervals, because 
injected drug is rapidly eliminated from the eye. This poses a substantial burden to 
patients, impose stress on medical personnel, and increase the costs of health care [3]. At
the same time, some diseases (e.g. AMD) are not responsive in all patients to the current 
medications and many retinal diseases are without any drug treatment [6].
Current limitations in retinal drug treatment address the importance to advance ocular drug 
delivery in order to enable more effective and long-acting treatments. In this regard, nano-
sized drug carriers (“nanoparticles”) have been investigated for targeted and sustained drug 
delivery [7]. They may increase retinal bioavailability, prolong drug retention in the eye, 
increase patient comfort and minimize adverse drug reactions [7,8]. After intravitreal 
injection, nanoparticles must transfer from the site of injection to the target tissues, thus 
highlighting the importance of understanding particle diffusion and interactions with the 
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vitreous gel [4,9]. Furthermore, retinal access of nanoparticles is restricted by vitreoretinal 
barrier [10,11], but information on retinal particle penetration is sparse, particularly in 
relevant animal models. 
To bridge this gap, this study was designed to explore the interactions of nanoparticles 
with ocular barriers, particularly in the case of liposomes, the most commonly used 
nanoparticles in biomedical applications [12,13]. Important formulation properties, such as 
surface coating, particle size and surface charge, may alter the pharmacokinetics of 
intravitreal liposomes, thereby affecting their clinical utility. In this regard, we have 
systematically investigated the barriers of vitreous humor and vitreoretinal interface using 
representative animal models. In addition, the potential of liposomal formulations was 
evaluated in the delivery of sunitinib, small molecule inhibitor of tyrosine kinase, a 
potential drug for choroidal neovascularization associated with AMD. This thesis provides 
insights to advance development of nanoparticle-based treatments in ophthalmology.
2
 
2   REVIEW OF THE LITERATURE
2.1 Anatomy and Physiology of the Posterior Eye Segment
Human eye is a small yet extremely complex organ, which provides visual perception. The 
eye can be classified into two segments: anterior and posterior segment (Fig. 1). Anterior 
segment includes cornea, iris, ciliary body, aqueous humor, conjunctiva and lens, but the 
detailed description of this segment is beyond the scope of this thesis. Posterior segment of 
the eye refers to the area behind the lens and consists of vitreous humor, retina and 
choroid. 
Figure 1 The human eye anatomy. Image reprinted from Delplace et al., Journal of Controlled 
Release 2015, with permission from Elsevier.
Vitreous humor
Vitreous is a transparent gel-like material of approximately 4 ml that occupies two-thirds 
of the eye volume [14]. Vitreous humor fills the space between the lens and retina and is 
normally acellular except a few hyalocytes in the cortical vitreous [15,16]. The gel matrix 
is a highly hydrated (98-99.7% water content) network consisting of structural proteins 
(collagen type II, IX, V/XI and VI) entangled with highly charged glycosaminoglycans 
(GAGs) [17]. The main components of vitreal GAGs include hyaluronic acid (HA), 
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chondroitin sulphate and heparan sulphate. Attraction of water and counter-ions by GAGs 
provides vitreous with resistance against compressive forces [17,18], while, collagen fibres 
stabilize the gel state by providing the tensile strength through the intermolecular covalent 
bonds [19]. Furthermore, vitreous contains several types of non-structural/soluble proteins 
including albumin, immunoglobulin, transferrin, coagulation proteins and complement 
factors [20-22]. The protein concentration in healthy human vitreous is between 0.5 mg/ml 
and 1.5 mg/ml [21-23]. Nonetheless, aging and various pathological conditions can induce 
changes in the concentrations and biochemical properties of vitreal proteins [24].
Retina
Retina forms the innermost part of solid posterior eye segment tissues. Retina consists of 
multiple neuronal cell layers (for details, see Fig. 2) and the neural retina is considered to 
be an extension of central nervous system. The neural retina is isolated at the anterior side 
from the vitreous by inner limiting membrane (ILM).  ILM is a basement membrane 
composed of extracellular matrix (mainly collagen and glycoproteins) and it acts as an 
anatomical and electrostatic barrier [11,25]. Posteriorly, retinal pigment epithelium (RPE) 
supports the retina. The outer side of the RPE is lined by acellular Bruch’s membrane.  The 
RPE cells form a monolayer with tight junctions and they regulate trans-epithelial transport 
thereby acting as a blood-retinal barrier (BRB), so called “outer BRB” [4]. RPE restrict the 
permeability of hydrophilic small molecule drugs as well as macromolecules. Nonetheless, 
macromolecules such as antibodies (149 kDa) poses 200-300 fold lower inward and 
outward permeability across the RPE (10 - 8 cm/s) compared to small drug molecules (255-
454 Da) [26].
Retinal function is vital for visual perception as it transduces the light information to neural 
impulses and transmit them to brain via horizontal cells, bipolar cells, amacrine cells, and 
finally ganglion axons in the optic nerve (Fig. 2) [27,28]. Two-thirds of the retina is 
nourished by the blood supply from retinal arteries, which forms the superficial capillaries 
near the surface of the retina and send branches to form intermediate and deep retinal 
capillaries. The outer retina consisting of photoreceptors is avascular in healthy eye, 
receiving oxygen and nutrients from the choroidal vessels [29]. The endothelium of retinal 




Figure 2 Schematic representation of detailed retinal structure. Retinal layers: inner limiting 
membrane (ILM), nerve fibre layer (NFL), ganglion cell layer (GCL), inner plexiform layer (IPL), 
inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), photoreceptors 
layer (PRL), retinal pigment epithelium (RPE). Image reprinted from Tavakoli et al., Journal of 
Controlled Release 2020, with permission from Elsevier.
Choroid
Choroid is a thin, densely pigmented and highly vascularized layer located between the 
retina and sclera. Principal function of the choroid, which accounts for 85% of total ocular 
blood flow, is to provide the blood supply to the outer retina [31]. Inner part of the choroid 
is smooth, choriocapillaries, which fenestrate into the Bruch’s membrane below the RPE. 
Unlike the inner part, the the external surface, suprachoroid, is irregular and attached 
strongly to the sclera [14]. Choriocapillaries are branches of the leaky large choroidal 
vessels and allows the plasma to diffuse along the Bruch’s membrane to nourish the 
avascular part of the retina especially the photoreceptors. The RPE, however, act as a 
barrier and prevents the fluid entry to the outer retina except for the nutrients and oxygen 
[29].
2.2 Posterior Segment Eye Diseases 
The main vision-threatening diseases affect retina and choroid. Many diseases of the 
posterior segment are associated with aging and/or underlying diseases (e.g. diabetes, 
hypertension, and atherosclerosis) [32,33]. Among these disorders, age-related macular 
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degeneration (AMD), diabetic retinopathy (DR) and glaucoma are the most prevalent 
diseases leading to increasing vision loss in aging populations worldwide (Fig. 3) [34,35].
Figure 3. Worldwide projected number of AMD and glaucoma incidence to the year 2030. 
Adopted from World Health Organization (WHO) report on vision, 2019 [36].
AMD is a progressive breakdown of macula which is a cone-dominated region in the retina 
[37]. Degenerative process in the macula gradually destroys the visual acuity and central 
vision. The number of patients suffering from AMD are increasing worldwide and 
expected to reach over 280 million by the year 2040 (≈1.5 times increase in 20 years) [38].
The complex pathogenesis of AMD is not completely understood. It involves a 
combination of metabolic, genetic and environmental factors [33,39,40]. The hallmarks of 
AMD include intracellular protein aggregates in the RPE and extracellular “drusen” 
deposits of lipids, proteins and complement factors in Bruch’s membrane [41]. Formation 
of drusen gradually causes perturbed exchange of oxygen and metabolites between 
choriocapillaries and RPE [42].
Clinically, the AMD is classified to dry-AMD and neovascular-AMD (also known as wet-
AMD) [39]. Dry-AMD is a more common type of AMD and accounts for 85-90% of 
diagnosed cases [43]. In the early stages, dry-AMD is defined by small to intermediate-
sized drusens, without significant sign of vision loss. In advanced stages, so called 
“geographical atrophy (GA)”, large drusen prevents vascular supply from choriocapillaris, 
resulting in malfunction, cell death in RPE and photoreceptors, eventually leading to loss 
of vision [37]. The neovascular form of AMD (nvAMD) involves pathological sprouting of 
new abnormal blood vessels to the outer retina and subretinal space [29]. Origin of these 
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vessels may be in the deep retinal capillary bed or choroidal vessels (choroidal 
neovascularization, CNV) [29]. Neovascularization may lead to accumulation of fluid and 
blood due the leakiness of neo-vessels. Pathogenesis of nvAMD is associated with an 
increased production of angiogenic growth factors, such as vascular endothelial growth 
factor (VEGF) [29,44]. However, evidences indicate also a link between immune-mediated 
events and neovascularization, suggesting that the elevated VEGF alone does not lead to 
nvAMD [33,45]. Among all AMD cases, 10-20% develop the neovascular form that causes 
much faster loss of vision than dry-AMD [37,46].
Diabetic retinopathy (DR) is the most common vision-threatening complication of 
diabetes [47]. Chronic hyperglycemia causes functional and structural damage to retinal 
capillaries and BRB breakdown. Increased permeability of retinal vessels results in blood
and fluid leakage to the back of the eye (microaneurysms, retinal hemorrhages) [47,48].
Accumulation of fluid in macula induces diabetic macular edema (DME) with 
inflammation and swelling of the macula, but this is less prevalent than DR [48,49]. In the 
advanced stage of DR, also known as proliferative DR, hyperglycemia can lead to retinal 
microvascular closure and retinal ischemia. As a result, hypoxic condition mediates the 
over-expression of VEGF that stimulates retinal neovascularization [29,50]. Retinal 
neovascularization originates from retinal vessels and often penetrating in the ILM and 
growing into the vitreous [50].
Glaucoma is a neurodegenerative disorder often caused by age-related increase of 
intraocular pressure (IOP) that may damage the inner layer of the retina (retinal ganglion 
cells, RGCs), and the optic nerve [39,51,52]. Elevation in IOP is usually associated with
perturbation in aqueous humor outflow from trabecular meshwork in the anterior part of 
the eye [53]. However, decreased age-related flexibility of the sclera can also induce the 
increased IOP [54]. Glaucoma is an important cause of irreversible vision loss (Fig. 3) [2].
2.3 Current Drug Delivery Strategies to the Posterior Segment of the Eye
The primary goals of any ocular drug delivery system are to maintain therapeutic drug 
concentration at the target site at long enough dosing intervals. Since drug concentrations 
at target sites depend on drug penetration across the barriers, it is essential to understand 
ocular barriers in drug development. 
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Ocular barriers are classified as static anatomical and dynamic physiological barriers that 
are essential in protecting the eye from xenobiotics, yet they pose challenges in ocular drug 
delivery [55]. The impact of barriers on drug delivery depends on the route of drug 
administration (Fig. 4).
Figure 4. Commonly used ocular route of administration. Image reprinted from Ilochonwu et al.
Journal of Controlled Release 2020, with permission from Elsevier.
Topical instillation is the most common method of ocular drug administration. It is non-
invasive and applicable in the home treatment of out-patients. In clinical practice, topical 
ocular formulations (eye drops, ointments, gels) are used to treat anterior segment diseases, 
such as dry eye, cataract, allergic conjunctivitis, infections and reduction of eye pressure in
glaucoma [56,57].
Poor drug bioavailability after topical administration does not lead to therapeutic drug 
concentrations in the posterior segment. Following topical administration, only 0.1 - 7 % of 
small molecular drugs reach the aqueous humor [58,59]. Such low absorption is due to the 
rapid pre-corneal drug loss by drainage of eye drop, tear turnover (1 μl/min) and systemic 
absorption across conjunctiva [3,60,61]. Besides pre-corneal loss, the multi-layered cornea 
poses an anatomical barrier that limits ocular drug absorption [62]. The cornea is 
composed of three main layers (epithelium, stroma, endothelium) of which the anterior 
tight epithelium significantly limits drug absorption, particularly the large and hydrophilic 
drug molecules [63-65]. Permeation of lipophilic small molecule drugs takes place mainly 
via transcellular route [66]. In addition to the trans-corneal route, topical drug may be 
absorbed through conjunctiva and sclera, across non-corneal route [67]. This route is 
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relevant in absorption of large and hydrophilic drugs [68], because conjunctival epithelium 
is leakier than the corneal epithelium [69]. Nonetheless, significant fraction of instilled 
drug dose (34-79%) is systemically absorbed into the blood circulation across conjunctival 
sac [68,69] and only the portion that is not eliminated by blood circulation reaches the 
sclera and may partly gain access to the choroid and retina. Altogether, even in the best 
cases, less than 0.001% of the topical dose reaches the retina, resulting in therapeutically 
inadequate drug concentrations [70,71]. 
Systemic route, including parenteral and per oral administration, can deliver drugs to the 
retina and vitreous through ocular blood flow. However, the process is hindered by BRB 
tight junctions in retinal capillaries’ endothelium (inner BRB) and RPE (outer-BRB). In
the similar manner, blood-aqueous barrier (BAB) in iris capillaries and ciliary endothelium 
prevent the drug entry into the posterior segment from blood stream. Moreover, efflux 
transporters in the RPE cells may limit access of drugs from blood stream to the retinal 
targets [72]. Other limiting factors include drug dilution in blood circulation, plasma 
protein binding and systemic clearance that significantly restrict retinal delivery of 
systemic drugs [73]. Consequently, this route may only be useful for small lipophilic drugs 
with broad therapeutic window (such as antibiotics) that can be administered in high and 
frequent doses to treat posterior segment diseases [3,74].
Intravitreal (IVT) injection is the current gold standard in drug administration to the 
posterior segment of the eye. IVT injection has been investigated for various 
pharmaceutical preparations, such as solutions, suspensions, micro/nano-particles and 
implants [75]. Direct delivery of therapeutics into the vitreous, provides immediate 
intraocular drug delivery and minimizes the required drug dose and systemic side effects. 
Although this route bypasses many barriers, there are still several barriers that must be 
taken into account in drug development [76].
Vitreous itself is the first barrier that must be overcome after IVT injection. After 
intravitreal administration, drug distribution depends on the compound properties (e.g. 
size, charge), and state of the vitreous [4]. The gel-like matrix of vitreous limits diffusion 
of large particles (> 550 nm), and particularly positively charged particles due to the 
electrostatic interactions with negatively charged hyaluronic acid [17,77,78]. In contrast, 
small drug molecules or protein drugs are almost freely mobile in the vitreous [4]. By 
aging, vitreous undergoes progressive liquefaction (synchysis) and collagen fibre 
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aggregation (syneresis) causing partial loss of gel-state and reducing the barrier role of the 
vitreous [18,79].
Physiological factors, such as intraocular convection and clearance pathways, can also 
affect drug distribution and elimination in the vitreous. Convection in posterior direction 
does not influence the distribution of small molecules, but it might affect distribution of 
larger compounds or particles [76,78]. Vitreal drug clearance takes place via two main 
routes: 1) anterior route to the anterior chamber and elimination via aqueous humor
turnover; 2) posterior elimination across the BRB [31].  The elimination rate and route of 
intravitreal therapeutics depends on their physicochemical properties. Large hydrophilic 
compounds (e.g. proteins) and particulate systems do not penetrate the BRB, and are 
mainly eliminated via anterior route, resulting in half-lives of several days [3,4]. Small 
drugs, particularly lipophilic compounds, are cleared via posterior route leading to the 
short intravitreal half-lives (<10 h) [80,81]. Therefore, their IVT administration as simple 
solutions, without sustained drug release, is not practical [80]. Since ocular half-life of 
small molecule drugs (<1000 Da) in general is less than 1 day, chronically used IVT 
injections are macromolecules (>50 kDa), such as potent anti-VEGF agents, with half-lives 
in the range of several days [31]. Even though concentration of endogenous vitreal proteins 
is much lower than in the plasma, protein binding may alter the drug levels in the vitreous,  
prolonging vitreal half-lives [21,24]. Nonetheless, a recent study on vitreal binding of 35 
small molecule drugs suggests that protein binding may only modestly affect the drug half-
life in the vitreous [24], while the half-life of 40 kDa nanobody was increased by 3-fold 
with a high affinity binding to albumin [24,82].
Retinal penetration is essential to obtain the therapeutic efficacy after IVT injections. In 
this respect, therapeutics must overcome vitreoretinal interface and inner limiting 
membrane (ILM), which is a basement membrane separating the vitreous from retina [83].
ILM is mainly composed of collagen type IV, laminin and negatively charged 
proteoglycans that form a physical barrier for retinal delivery [84,85]. Retinal permeation 
across the ILM depends on multiple factors, such as compound or particle properties (e.g. 
size and charge) and endogenous factors (e.g. ILM thickness, aging, disease-related 
changes, morphological differences) [84]. Moreover, the ILM properties differ between 
species [11] and the ILM thickness and composition may become stiffer by aging [86]. For 
example, at older age the concentration of collagen type IV may increase, while levels of 
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laminin may decrease [86]. The thickness of foetal ILM is about 70 nm and later it will 
become thicker, reaching 2 μm (TEM) or 4 μm in the posterior pole (based on atomic force 
microscopy (AFM) measurements) [86-88]. In the fovea and at the rim of optic nerve, the 
ILM is rather thin (< 140 nm), which may be essential for the normal vision [89-91]. ILM 
thickening can be associated with the slow degeneration of the collagen fibres, while the 
protein synthesis goes on at the vitreoretinal interface during the entire life-span [86,92].
Besides age-related changes, the properties of ILM might be altered in disease state.
Diabetes-related ILM thickening and increased collagen type IV synthesis have been 
reported in long-term diabetes [93]. ILM might be even broken in proliferative diabetic 
retinopathy [94,95].
Negatively charged components of the ILM restrict the permeation of cationic compounds, 
while the anionic and neutral drug molecules or drug delivery systems are less hindered by 
this barrier, unless their size becomes a limiting factor [11,76,96]. According to Pitkänen et 
al., retinal permeation of intravitreal macromolecules and particles is predominantly 
influenced by the charge of the permeant. It was evident that FITC-dextran of 2000 kDa 
(mean molecular weight) and negative charges diffused into the retinal layers, but 20 kDa 
positively charge FITC-poly-L-lysin failed to pass across bovine ILM [97]. In addition, 
several studies suggest that the retinal permeation of the macromolecules depends on the 
molecular weight [85,98-100]. According to these investigations, Fab’ fragments (48 kDa) 
diffuse into the retina, while there is a controversy on the retinal permeation of the full-
length antibody such as bevacizumab (148 kDa) [101]. Transient enrichment of the 
antibody at the ILM prior to retinal permeation was evident in many of observations [11],
but the extent of retinal permeation of full-length antibodies remains unclear.
Other local routes of administration: Drug delivery to the posterior segment can be 
accomplished via other route of administrations such as subretinal, periocular and 
suprachoroidal [102,103]. Subretinal route bypasses the ILM barrier, because drug is 
injected directly between the RPE and photoreceptors. However, these injections require 
substantial expertise and repeated injections are not feasible [93]. In contrast, periocular 
drug administration is less complicated, involving injection of drug solution or suspension 
into the subtenon or subconjunctival space. Such injections are widely used in anterior 
segment drug delivery and they are less invasive than IVT injections. However, the 
barriers (sclera, RPE, conjunctival and chroroidal blood flows) limit retinal bioavailability 
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to about 0.1% [104-106]. Subtenon injection is more effective than subconjunctival 
injection, resulting in 5-fold increase in bioavailability, but still the levels are low [107]. In 
suprachoroidal injection, the drug is delivered to the space between the sclera and choroid. 
The sclera is bypassed with this method offering higher bioavailability compared to 
periocular route [108]. In this case, retinal bioavailability is limited by choroidal blood 
flow and the RPE, but choroidal bioavailability is nearly complete. However, choroidal 
blood flow removes drug rapidly after injection unless special formulations are used.
Suprachoroidal delivery is still at experimental stage, not yet in the clinical practise (e.g. 
suprachoroidal microneedles, phase III of clinical trial) [109,110].
2.4 Current Therapies for the Posterior Segment of the Eye
Increasing prevalence of posterior segment eye diseases in aging population demands 
development of effective therapeutics. In this respect, many experimental and clinical 
ocular drug products have been designed for different routes of administration and duration 
of action. Inflammation and elevated levels of VEGF are recognized as major features in 
many retinal and choroidal diseases such as AMD, CNV, DR, DME and retinal vein 
occlusion [111,112]. Therefore, the most important and promising medications include 
anti-VEGF agents, anti-inflammatory drugs and neurotrophic factors that are given as IVT 
injections and implants [4]. Also, systemic administration of liposomal verteporfin as 
photodynamic therapy is still in clinical use. In this case, verteporfin (approved in 2000) 
produces short-lived oxygen free radical in the presence of laser light to destroy blood 
vessels [113]. It is indeed the only systemic treatment for nvAMD, but its efficacy does not 
match that of IVT anti-VEGF therapy. Photodynamic therapy requires frequent visits to the 
clinics that leads to poor patient compliance. 
2.4.1 Intravitreal Anti-VEGF 
IVT injection of anti-VEGF agents is the most promising strategy for posterior segment of 
the eye diseases [5]. Blocking the VEGF-pathway can inhibit the pathological vessel 
growth and leakiness. In this respect, the most common strategy is to prevent binding of 
VEGF-A to its receptors. The first VEGF-specific humanized monoclonal antibody, 
bevacizumab (Avastin®), was approved by the U.S. Food and Drug Administration (FDA) 
in 2004 for metastatic colorectal cancer [5]. Bevacizumab binds to all isoforms of VEGF-A
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and VEGF-B and it is widely used off-label in nvAMD and DME. Investigations on 
VEGF-mediated ocular neovascularization led to development of pegaptanib (Macugen®,
PEGylated aptamer against VEGFA165) and ranibizumab (Lucentis®, Fab’ fragment of 
bevacizumab) which received FDA approval for nvAMD in 2004 and 2006, respectively 
[5,112]. Soluble VEGF receptor aflibercept (Eylea®) was approved in 2011 for IVT 
injection in nvAMD and all stages of DR. It is a recombinant fusion protein, also known as 
VEGF Trap, consisting of binding domain of VEGF receptor-1 (VEGFR-1) and VEGFR-2
fused to Fc fragment of human IgG1 [114]. Aflibercept binds to all isoforms of VEGF-A
and VEGF-B at higher affinity than bevacizumab [5].
All currently approved anti-VEGF biologics are formulated as sterile solution in single-
dose vial or pre-filled syringes for IVT injection (maximum volume of injection is 100 μl). 
Given the hydrophilicity and molecular weight of these macromolecules, approximately 
90% of the dose is eliminated through anterior route resulting in vitreal half-lives in the 
range of a week [57]. Hence, injections at 4 to 8 weeks intervals are needed for anti-VEGF 
proteins [112]. The IVT injection interval has been extended to 8-12 weeks in the most
recently approved (2019) anti-VEGF agent brolucizumab (Beovu®) that is a humanized 
monoclonal single-chain Fv (scFv) antibody fragment [115]. It binds to major isoforms of 
VEGF-A, including VEGFA165 [116]. Also, abicipar pegol, antibody mimetic small protein 
against VEGF-A, has potential to stabilize vision at 12-weeks dosing intervals based on the 
Phase III clinical trial results, but FDA did not approve it for nvAMD treatment due to the 
incidence of intraocular inflammations in mid-2020 [117]. Despite the substantial benefits 
of such therapeutic options, there are unresolved challenges in the treatment of posterior 
segment diseases. For instance, one-third of the patients with DR are not responsive to 
anti-VEGF treatment [118]. Therefore, photodynamic therapy remains the only treatment 
option in those cases until more effective therapy to target leaky retinal blood vessels will 
be introduced [119]. Likewise, almost 40% of nvAMD patients demonstrate sub-optimal 
response to the anti-VEGF treatment [120]. Current approved doses are maximal and no 
extra efficacy can be achieved at higher doses in nvAMD and DR [121]. Currently, clinical
under-treatment is partly related to inadequate number of injections that is due to the 
reduced patient compliance. The IVT injections are occasionally associated with rare, but 
serious, adverse effects, such as retinal detachment, increased IOP, retinal haemorrhage, 
cataract and endophthalmitis [122-124]. In addition, IVT injections must be performed by 
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ophthalmologists or expert nurses and they impose a major burden on healthcare. 
Prolonged duration of the injections would be beneficial. 
2.4.2 Corticosteroids
Considering the substantial evidence on the underlying role of inflammation in the 
pathogenesis and progression of retinal diseases, one treatment strategy is to block the 
inflammatory pathways. Intravitreal corticosteroids, such as dexamethasone and 
fluocinolone acetonide, have shown anti-inflammatory and anti-angiogenic properties 
resulting in promising outcomes in DME, particularly in its advanced stages [125]. The 
half-lives of injected small molecule solutions are only a few hours, since they permeate 
through BRB posteriorly [4,57]. Suspension dosage form of small molecule drugs 
including corticosteroids, however, can prolong the vitreal retention owing to the slow 
dissolution rate [126]. For instance, IVT suspensions of triamcinolone acetonide 
(Triesence® and Trivaris®) showed the extended vitreal residence time of up to a few 
months [127]. IVT corticosteroids are also formulated as intravitreally injectable implants 
that are used at 6-month (dexamethasone, Ozurdex®) or 36-month (fluocinolone acetonide, 
Iluvien®) intervals [128]. The implants avoid the side effects of multiple IVT injections, 
but the vitreous traction and long-term corticosteroid therapy may be associated with 
cataract and/or elevated IOP [129,130]. Furthermore, over longer time periods, they may 
increase the risk of glaucoma and systemic side effects, such as gastrointestinal upset, 
hypertension and osteoporosis [131,132].
2.5 Emerging Therapies and Drug Delivery Systems
Over the past two decades, several therapeutic agents have been approved for nvAMD, 
DME and DR, and many more are in the clinical trials. Consequently, continuous efforts 
have focused on 1) targeting multiple pathways that are linked with pathological 
neovascularization and 2) developing the innovative drug delivery systems for existing 
drugs to attain prolonged therapeutic concentration at the target site thus avoiding repeated 
IVT injections [133].
In this respect, other VEGF signalling pathways have been explored. One strategy is to
block the VEGFR signalling by tyrosine kinase inhibitor (TKI) drugs (e.g. sunitinib, 
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axitinib, vorolanib, pazopanib) in order to stop the neovascularization [5,134,135]. GB-102 
(GrayBug Vision™), reservoir of sunitinib maleate in polymeric microparticles, is a 
potential sustained-release IVT formulation for the treatment of nvAMD that is in phase II 
clinical trial [136]. In addition, sunitinib has shown neuroprotective effect by blocking the 
dual-leucine zipper kinase (DLK inhibitor) which makes it an interesting option for 
treatment of retinal disorders [137,138]. IVT axitinib implant (OXT-TKI, Ocular 
Therapeutix™) has reached phase I clinical trial for the treatment of nvAMD and DME 
[135,139]. Similarly, Durasert™-TKI (EyePoint™) implant has been investigated for 
vorolanib delivery in preclinical studies for nvAMD and DR treatment [140,141]. In 
another study, per oral pazopanib was used in CNV mouse model to suppress 
neovascularization via inhibition of VEGFR and platelet-derived growth factor (PDGF) 
receptor [142].
Blocking the VEGFR-2, the main mediator of neovascularization, is another intriguing 
strategy. Anti-VEGFR-2 monoclonal antibodies such as tanibirumab and ramucirumab 
(Cyramza®) suppress the neovascularization by inhibiting the endothelial cell migration 
and proliferation [5,143]. This effect was observed in preclinical studies on laser-induced 
CNV rat model, but there are no ongoing clinical studies based on this approach.
Given the multiple mechanisms in retinal and choroidal disorders, more efficient outcomes 
may be attained by targeting multiple pathways of neovascularization. Preclinical studies 
on PDGF inhibition in combination with anti-VEGF-A agents showed promising results 
for the treatment of nvAMD [144]. This approach is in phase III trials using a combination 
of pegpleranib (Fovista®, anti-PDGF aptamer) and ranibizumab [140]. In addition, 
faricimab is under investigation in phase III clinical trial for the treatment of DME and 
nvAMD. Faricimab is a bispecific antibody targeting angiopoietin-2 and VEGF-A
signalling pathways to stabilize the blood vessels and limit permeability, which has shown 
enhanced efficacy over anti-VEGF monotherapy [6].
Some posterior segment eye diseases are characterized by inflammation (immune cell 
infiltration) and neural cell degeneration, but anti-VEGF compounds do not affect these 
factors [145]. In addition to corticosteroids, inhibition of complement proteins (e.g. C3, C5 
and C9) have shown potential in AMD treatment [146-148]. Hemera Biosciences 
developed a viral-vector mediated gene therapy (HMR59) to inhibit the C9 complement 
cascade. This product is in phase I clinical trial for nvAMD [146].
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Various cytokines and growth factors protect neural retina from degeneration. For instance, 
ciliary neurotrophic factor (CNTF) showed preclinical protective properties against 
neurodegenerative disorders (e.g. in glaucoma). However, CNTF has a short vitreal half-
life necessitating frequent IVT injections [129]. Therefore, IVT implant (Renexus®) was 
developed utilizing encapsulated cell technology (ECT) in which genetically-modified 
cells secrete CNTF to the vitreous over a prolonged time [149]. This approach is in Phase 
III of clinical trial for glaucoma [150,151].
During the past two decades, gene delivery gained interest for treatment of posterior 
segment eye diseases such as AMD, glaucoma and some inherited retinal diseases [152-
155]. Herein, therapeutics including DNA, mRNA and regulatory RNAs (e.g. siRNA and 
miRNA) must be shuttled into their specific cytosolic or nuclear targets in retinal cells such 
as RPE and photoreceptors [156,157]. The route of administration depends on the target 
site, yet, given their negative charge, large molecular weight and the lability of these 
compounds in biological environment, carrier systems (viral and non-viral) are usually 
required for intracellular delivery. Despite several advantages of non-viral carriers, such as 
lower immunogenicity and higher loading capacity, viral-based carriers have demonstrated 
the most effective transfection of retinal cells [158]. Viral vectors are mainly based on 
modified adeno-associated virus (AAV) family [140,159]. Most successful retinal nucleic 
acid transfer experiments have relied on sub-retinal injections, because vitreoretinal 
interface hinders the access of the viral and non-viral particles to the retina. Strategies to 
overcome this barrier are thus needed. Recently, clinical trial on intravitreal injection of 
ADVM-022 was launched, involving AAV vector carrying cDNA for aflibercept, (phase I 
clinical trial for nvAMD) [160]. This approach offers durable expression of anti-VEGF 
proteins following a single dose administration for treatment of nvAMD.
Parallel to the emerging therapeutics, innovative drug delivery systems and strategies have 
been developed to prolong the dosing interval of anti-VEGF therapeutics and 
corticosteroids. Table 1 shows examples of systems for posterior segment eye diseases. 
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Table 1. Long-acting delivery systems for the treatment of posterior eye segment
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Nevertheless, most aforementioned technologies require invasive administration methods, 
such as surgical procedures to implant or to remove devices. Consequently, 
nanotechnology-based drug delivery systems may offer a promising alternatives to 
overcome some of the limitation of current therapies, particularly by providing possibilities 
for retinal permeation and cellular delivery.
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2.6 Nanotechnology-based Drug Delivery Systems           
Nanotechnology has gained significant research interest in medicine during the past 
decades. In this regard, the use of nano-sized carriers (below 1000 nm in diameter) have 
been investigated for drug delivery to ocular target tissues in order to manage the posterior 
segment disorders. Nanoparticles may enable increased intraocular retention, extended 
drug release and distribution to the tissues. As a result, they may improve the efficacy of 
treatment efficacy, enable the use of difficult compounds as therapeutics and prolonging 
the drug dosing intervals [118,129].
Nanoparticles can be classified based on their composition. Numerous types of materials 
have been applied for ocular drug delivery systems, such as synthetic polymers (e.g. 
polymersomes, polymeric micelles, and hydrogels), proteins (albumin nanoparticles), 
lipids (e.g. liposomes, solid lipid nanoparticles (SLN)), and inorganic compounds (e.g. 
gold-nanoparticles) [118,165]. To this end, intravitreal injection of nanoparticles have been 
explored for retinal delivery of various therapeutic compounds, such as small molecule 
drugs, peptides, proteins and small regulatory RNAs [7,8,166,167].
2.6.1 Nanostructured drug delivery systems for retinal and choroidal diseases
Polymeric nanoparticles have been studied as sustained drug delivery systems for back of 
the eye disorders. The most commonly investigated polymers include PLGA copolymers 
(poly (lactide-co-glycolide), PLA (poly lactides), PCL (poly (caprolactone)), poly (methyl 
methacrylate), chitosan and hyaluronic acid (HA) [7,163]. FDA approved PLGA gained 
interest in ocular drug delivery based on its biodegradability and biocompatibility [7,118].
Several preclinical IVT studies have utilized PLGA in polymeric nanoparticles to control 
the choroidal neovascularization and retinal degeneration. Prolonged inhibition of 
neovascularization over 6 weeks has been observed with sustained release bevacizumab-
loaded PEG and PLGA nanoparticles (particle size = 819 nm) and dexamethasone-loaded 
PLGA nanoparticles (particle size = 253 nm) in laser-induced CNV rat models [168,169].
Recently, polymersomes (particle size = 100 nm) and polymeric micelles showed enhanced 
vitreal half-life of 32 days and 9 days, respectively, in rabbits suggesting a promising 
retinal drug delivery system (unpublished). 
Besides synthetic polymers, endogenous protein, such as human serum albumin (HSA), 
has been evaluated for retinal drug delivery via IVT administration. The albumin 
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nanoparticles were first approved by FDA for intravenous delivery of paclitaxel 
(Abraxan®) in breast cancer treatment, but given its numerous interesting properties for 
extended drug delivery, it also gained interest for ophthalmic application [170].  In this 
respect, Kim et al. demonstrated that HSA nanoparticles (particle size = 152.8 nm) loaded 
with small drug molecule (brimonidine) have neuroprotective effect in optic nerve crush 
rat model lasting up to 14 days [171].  In-situ forming hydrogels are another polymeric-
based delivery systems which have recently received attention for long-term release of 
biologics following the IVT administration [172,173]. For instance, hyaluronic acid (HA)-
dextran hydrogels showed sustained delivery of bevacizumab at the therapeutics 
concentration for up to 6 months in rabbits [174].
Solid-lipid nanoparticles (SLNs) offer several beneficial features, such as controlled 
release of hydrophobic and hydrophilic drug molecules, biocompatibility, stability and ease 
of production. Nonetheless, the limited loading capacity of SLNs restrains its application 
for prolonged ocular drug delivery [175]. Instead, SLNs were successfully used as gene 
vectors for plasmid transfection of photoreceptors in mouse models, preventing loss of 
photoreceptors 2 weeks after IVT injection [176]. Nano-structured lipid carriers (NLCs) 
are more advanced generation of lipid-based nanoparticles with higher drug loading 
capacity compared to SLNs [7]. In the eye, NLCs have been investigated mostly for the 
anterior segment drug delivery. Araujo et al. explored the use of NLCs for triamcinolone 
acetonide delivery to the posterior segment via topical administration in mice, yet, no drug 
was detected in the intraocular tissues after 160 min [177].
2.6.1.1 Stimuli-responsive nanoparticles
Besides sustained-release capability, nanoparticles can be designed in order to provide 
stimuli-responsive drug release. In this respect, the external signals, such as light, heat, and 
pH are used for triggered drug release [166,178]. Given the unique structure of the eye, 
light-triggered drug release is an intriguing solution that can be leveraged for extending the 
IVT injection intervals of both lipid-based and polymer-based nanocarriers [179]. Light-
triggered release of nintedanib-loaded polymeric nanoparticles is an example of such 
design, which allowed 10 weeks of CNV suppression in rat model [180]. Moreover, light-
triggered hydrogel systems based on agarose-coated gold- nanoparticles showed 
triggerable release of bevacizumab for 6 months [181].
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2.6.1.2 Target-specific nanoparticles 
Another valuable feature of the nanoparticles is their potential for target-specific delivery 
to retinal cells via surface engineering. Particularly, polymeric materials can be modified 
with ligand conjugation towards fabrication of targeted drug delivery systems. Ligand-
targeted drug delivery, so called “active targeting”, is based on specific interactions 
between a ligand and receptor in the target cells (e.g. folate-receptor mediated targeting to 
the RPE cells) [166]. Delivery of triamcinolone acetonide with folate-coated PEG-PCL 
nanoparticles into ARPE-19 cells was significantly higher than with uncoated carriers 
[182]. Hyaluronic acid (HA) is also a potential targeting moiety that has been applied for 
drug delivery to CD44-expressing cells, such as Müller cells and RPE cells [183-185]. For 
instance, HA-modified HSA (particle size = 252.7 nm) could significantly improve 
therapeutic efficiency of connexin-43 mimetic peptide (Cx43 MP) to suppress the 
inflammatory process and prevent the RGCs loss in rats with retinal-ischemic condition 
[186]. Furthermore, VEGF-grafted magnetic nanoparticles (nanomag®) revealed promising 
retinal drug delivery strategy through cell-specific targeting in zebrafish [187].
2.7 Liposomes for the Posterior Segment Eye Diseases  
Liposomes were first introduced as drug delivery systems for cytotoxic agents in 1965 and 
nowadays several clinically approved liposomal formulations are used, including Doxil®,
Ambisome®, DaunoXome®, DepoCyt®, Mayocet®, Visudyne®, Lipo-Dox® DepoDur™,
Marqibo®, Onivyde™ and Vyxeos® [176,188]. Liposomes are spherical vesicles that 
include an aqueous core encapsulated with lipid bilayers of amphiphilic phospholipids (e.g. 
phosphatidylcholine and phosphatidylethanolamine) [189]. Given their biphasic structure, 
hydrophilic and hydrophobic drug molecules can be entrapped in the aqueous compartment 
and lipid bilayer, respectively. Liposomes are classified as SUV (small unilamellar 
vesicles, 20-200 nm), LUV (large unilamellar vesicles, 200-1000 nm) and MLV 
(multilamellar vesicles, > 500 nm) [190]. Intravitreal liposomes are typically in the 
submicron size range [191]. In general, lipid film hydration results in MLVs, which can be 
further processed to form SUVs via sequential extrusion through polycarbonate filter 
membranes to achieve desired particles size. Sonication and microfluidics are alternative 
methods for particle size adjustment.
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Figure 5: Schematic representation of different liposome structures.
Liposomes offer several advantages as an ocular drug delivery system including high 
biocompatibility, stability, robustness and ease of production, high loading capacity and 
biodegradation [192]. Furthermore, they can prolong the intraocular half-life [126]. In this 
respect, the lipid-bilayer permeability can be tuned with the choice of lipid composition; 
saturated phospholipids with long hydrocarbon chains provide more stable and less leaky 
bilayers [189]. From the pharmaceutical point of view, liposomes can improve the 
solubility of poorly water-soluble drugs, such as corticosteroids, TKIs and IOP-lowering 
agents [166]. Moreover, they can protect the macromolecules (e.g. proteins and RNAs) 
from enzymatic degradation. The net charge of the liposomes affect their ability to 
overcome ocular barriers. Liposomes are commonly composed neutral, cationic and/or 
anionic lipids and, in addition, PEG-conjugated lipids are used to prepare “stealth-
liposomes” with improved stability and intravitreal half-life [192]. In addition, surface-
coating with HA, an endogenous vitreal component, is an interesting alternative to 
PEGylation [183,193].
To date, various intravitreal liposomal formulations have been investigated for the ocular 
sustained drug delivery. Tacrolimus-loaded liposomes, for instance, resulted in significant 
reduction of intraocular inflammation in retinitis rat model over 14 days following the IVT 
injection [194].  In addition, liposomes were successful in many preclinical studies to 
prolong the therapeutic concentrations of antibiotics (e.g. amphotericin B, ciprofloxacin) 
[195,196]. This indicates the potential of liposomal carriers to increase the efficacy of 
hydrophobic small drug molecules. In addition, IVT injection of liposomal bevacizumab 
showed five-times higher vitreal drug concentration compared to bevacizumab alone after 
42 days [197]. Beside drug delivery, liposomes have been explored for gene delivery to 
retinal targets. In gene therapy by liposomes, the main lipid components are cationic for 
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binding and condensation of the nucleic acids [198]. The formulation are often PEGylated 
to provide stability in the vitreous [198]. Intravitreal administration of PEGylated 
liposome-protamine-HA loaded with siRNA (particle size = 132 nm) resulted in reduction 
of neovascularization at least for 2 weeks by inhibition the VEGFR-1 expression in laser-
induced CNV rat model [199].
Targeted drug delivery to the posterior segment of the eye is feasible via either passive or 
active targeting [7]. In the passive mechanism, liposomes diffuse across permeable 
membranes without any ligands, while active targeting involves functionalization of the 
liposome surface with targeting ligands that will bind to ocular target cells [12,200]. In this 
respect, HA-coated lipoplexes showed eight-fold higher transfection efficiency compared 
to unmodified liposomes in the ARPE-19 cells [193]. In addition, Wang et al. designed a 
targeted liposome via peptide-conjugation, 12-aminoacids peptide coded as YSA, in order 
to reach specific delivery of doxorubicin to the RPE cells. The in vivo study of YSA-
liposomes in CNV rat models showed significantly higher inhibition of neovascularization 
compared to unmodified liposomes [201]
As it was discussed in the previous section, the concept of activated drug release is of great 
interest in the field of ocular drug delivery. In particular, the light-responsive formulation 
would be attractive as the eye is accessible to light. This strategy was studied in several
clinical trials for photodynamic intravenous therapy of nvAMD using Visudyne®
(liposomal verteporfin) and IVT anti-VEGF antibodies such as ranibizumab and 
bevacizumab to manage the CNV [179,202]. Later, Lajunen et al. developed new type of
light-activated liposomes with on-off light triggered release mechanism [203]. Toward this 
goal, the photosensitizer (indocyanine green (ICG)) is loaded to the liposomal membrane 
for temporal and spatial controlled drug release. Herein, ICG converts the near-infrared 
(NIR) laser energy to heat, consequently converting the membrane leaky, thereby allowing
drug release [203,204].
Altogether, liposomes can be considered as potential drug delivery system to transport 
therapeutic compound into the retina to obtain more efficient and long-acting treatment. 
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2.8 Models to Study the Retinal Drug Delivery
Despite some successful preclinical studies on nanoparticle-based retinal drug delivery, 
their translation to clinical use remains challenging owing to complicated ocular barriers 
that limit access to the posterior segment tissues. Several barriers are avoided by IVT 
injection, yet for successful retinal drug delivery the nanoparticles must overcome two 
main hurdles after IVT administration: vitreous and ILM. Consequently, it is essential to 
explore whether the nanoparticles are able to overcome these barriers to reach retinal 
targets. Currently, most preclinical results on retinal nanoparticle delivery are based on in
vivo studies with mice and rats. Given the small vitreous volume and structurally different 
ocular barriers, translation of such observations from the rodents to clinical application is 
troublesome. Over the last two decades, several in vitro and in vivo methods have been 
investigated to expand our understanding on interactions of drug delivery systems with the 
ocular tissue barriers. 
2.8.1 Methods to study the barrier role of vitreous
The vitreous may restrict diffusion of nanoparticles as discussed in section 2.3. The 
mobility in the vitreous depends on the characteristics of the particles as well as the 
physiological state of the vitreous. Particle size, surface charge, surface coating (e.g. PEG 
and hyaluronic acid), material properties and vitreal-nanoparticle interactions (protein 
binding and interaction with other components of the vitreous) can influence the diffusion 
of nanoparticles in the vitreous. In the early in vitro studies, diffusivity of particles was 
measured in isolated vitreous (often bovine or porcine) using fluorescence-based analysis 
(e.g. microscopy and flow cytometry). For instance, Pitkänen et al, studied the cellular 
uptake of cationic lipoplexes to the human RPE cell line (D407) that was covered by a thin 
layer of bovine vitreous. They further, concluded that the vitreous substantially impedes 
the mobility of lipoplexes resulting in 2-30 fold decrease in the cellular uptake due to the 
electrostatic interactions with vitreal components [77]. In another approach, the vitreal 
mobility of fluorescent polystyrene nanospheres and lipoplexes and their PEGylated 
variants were studied using fluorescence recovery after photobleaching (FRAP) technique 
[205]. Nonetheless, such in vitro techniques involved disruption of structural network of 
vitreous due to experimental manipulations [76,205].
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Ex vivo approaches may provide improved models of the in vivo condition. In this regard, 
Martens et al. and Xu et al. suggested an ex vivo bovine model to study the diffusion of 
drug delivery systems with single particle tracking (SPT) technique in which the mean 
square displacement (MSD) is determined from the microscale trajectories of particles’ 
motion [206,207]. The data on particle motion was obtained with confocal microscopy. 
Unfortunately, Martens et al. injected the polystyrene nanospheres and polyplexes close to 
the anterior part of hyaloid membrane instead of central vitreous [207]. Later, single 
particle tracking was applied by Käsdorf et al. to compare the diffusion coefficient of 
liposomes and polystyrene nanoparticles with various charges (particle size ≈ 200 nm) in 
bovine, porcine and ovine vitreous [208]. Unlike the previously mentioned studies, the 
vitreous was not kept in the eyeball, potentially leading to alterations in the vitreous 
structure. In another study, the mobility of three liposome types (cationic, neutral and 
anionic, particle size ≈100 nm) was measured using fluorescence correlation spectroscopy 
(FCS) in porcine eye [209]. While single particle tracking involves live tracking of 
particles in the vitreous, in the FCS approach the eyes are snap frozen following the IVT 
injection (using 27 G needle) to study the bio-distribution of labelled nanoparticles.
In conclusion, each method has its merits and disadvantages. However, multiple factors 
affect the diffusion of the nanoparticles in the vitreous. For example, protein corona may 
be formed on the nanoparticle surface upon their exposure to the vitreous [195]. This has 
been investigated with a combination of surface plasmon resonance and proteomics (using 
mass spectrometry). This may further define the biological identity of nanoparticle and 
dictate their interactions with vitreal components and cells. Consequently, additional in-
depth investigations are required to understand the behaviour of drug delivery systems in 
the vitreous. 
2.8.2 Methods to study barrier role of vitreoretinal surface
The vitreoretinal (VR) interface is another important barrier hampering the retinal 
permeation of nanoparticles [76]. ILM is the important component of this barrier, but the 
precise cut-off size of the barrier has remained elusive as there are significant interspecies 
differences [11,96]. Similar to other barriers, ILM can reduce or block the permeation of 
nanoparticles into the retina depending on the physicochemical characteristics of these 
carriers. Positively charged nanoparticles are unable to overcome the ILM [11,96]. Even 
though, efficient penetration of niosomes and cationic lipid-based nanoparticles was 
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shown, these experiments were conducted in the rat retina [210,211] that has much thinner 
and less complex ILM than the larger species, like humans. Likewise, size-dependence of 
retinal nanoparticle penetration is not well understood, since almost all previous studies 
were performed in small animals with leaky and thin ILM. Consequently, ex vivo models 
may provide means to evaluate retinal permeation of nanoparticles across vitreoretinal 
surface. In this regard, retinal explant cultures enable studies of drug and delivery system 
permeation into the retina after IVT administration. Such ex vivo models have been widely 
employed to study the viral and non-viral nanoparticles such as magnetic, gold and silver 
nanoparticles [212-214]. However, except few studies [215,216], current knowledge is 
based on murine retinal explant studies [212-214,217].
Diffusion chambers have been applied to quantify drug transport across ocular membranes, 
such as ILM, neural retina, RPE and choroid [218-222]. In this set-up, the membrane is
mounted between donor and receiver chamber, and at certain time points, permeated
compound can be quantitated in the receiver phase. To date, this approach have been 
investigated using human, bovine, porcine and rabbit tissue membranes to study the 
permeation of small molecule drugs, macromolecules (e.g. bevacizumab, FITC-dextran) 
and nanoparticles [223]. Isolated perfused eye model is another ex vivo method that was 
first developed for biological studies, but is also applicable in pharmacokinetic studies 
[224]. This model has been applied in ocular studies in which ciliary artery is cannulated 
and perfused [224,225]. Bio-distribution of IVT injected therapeutics can be quantified in 
ocular tissues with mass spectrometry [226,227]. Furthermore, nanoparticle localization in
ocular tissues can be detected with immunohistochemistry after cryosectioning. Perfused 
eye, however, is a complex method that allows only short (3-9 hours) experiments limiting 
its applicability in drug delivery studies [228]. A systematic research is needed to define 
the factors that affect retinal penetration of drug delivery systems. Such information can be 
further utilized in rational design of nanoparticles for retinal drug delivery. 
2.8.3 Methods to study the anti-neovascularization response in vivo
As explained in previous sections, nvAMD is characterized by CNV. Along with the 
continuing attempts to introduce new treatments to suppress the neovascularization, 
experimental animal models are essential to screen the new therapeutics. Given the 
contribution of several cell types (e.g. endothelial cells and inflammatory cell) in CNV 
[229,230], there is no representative in vitro model to recapitulate the complexity of the 
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disease. Nonetheless, there are few reports on ex vivo evaluation of neovascularization 
based on choroidal tissue of rats or mice [231,232]. Such experimental analysis so called 
“choroid sprouting assay” is based on isolation of choroid from animal model and 
incubation in Matrigel™, in which the tube-like sprouting area is quantified to determine 
the anti-neovascular effects of pharmacological interventions [232]. This approach, 
however, requires extensive optimization to obtain robust condition while the model is 
applicable only for few days. 
In vivo models are considered to better mimic of the neovascular disease of the patients. In 
this regard, CNV can be established in various animal models (e.g. rat, mouse, rabbit, pig 
and monkey) by means of laser photocoagulation, sub-retinal injection of VEGF or 
oxidative stress induction, or by applying transgenic animals to over-express the VEGF
[233-235]. Currently, laser-induced rupturing of the Bruch’s membrane is the most
accepted preclinical CNV model [236]. In this method, newly formed blood vessels grow 
into the sub-retinal space mimicking the biological processes associated of nvAMD [236].
Laser-induced CNV mouse model is the most common choice for drug testing [235]. In 
addition to small molecule drugs, it has been applied to evaluate the efficacy of biologics,
such as siRNA, recombinant proteins, antibodies, and nanoparticles [237,238]. Larger 
animals are better for long-term studies with CNV present for several months [239]. Larger 
animals also share better structural similarity with the human eye, but the cost of housing 
and ethical issues limit their application in drug screening [235]. Even though mouse 
model does not completely portray the complexity of clinical CNV pathology (e.g. absence 
of macula), it has helped significantly in understanding the key regulators that are involved 
in the progression of nvAMD. Furthermore, the model has been essential in the 
development of current medications, such as ranibizumab and aflibercept [236,240,241].
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3   AIMS OF THE STUDY
The overall aim of this thesis was to provide better understanding of ocular barriers related 
to retinal drug delivery with intravitreally administered nanoparticle formulations. Such 
information should facilitate development of drug delivery systems for treatment of 
posterior segment eye diseases. This study was performed using preclinical in vitro, ex vivo
and in vivo approaches.
The specific aims of the thesis were to:
1. Explore the intravitreal diffusion of lipid-based nanoparticles in ex vivo porcine 
model to reveal information about the relationship between particle characteristics 
and vitreal diffusivity. 
2. Investigate the protein corona formation on liposomal surfaces in the porcine 
vitreous with surface plasmon resonance and mass spectrometry. 
3. Investigate the role of liposome properties on their permeation from vitreous to the 
retinal layers.
4. Develop a liposomal drug delivery system for intravitreal sunitinib delivery and 
test its activity in choroidal neovascularization model in vivo.
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4   OVERVIEW OF THE MATERIALS AND METHODS
The materials and methods applied in this thesis are summarised in Table 2. UR refers to 
unpublished results. Additional detailed information of the methods is shown in the 
original publications that are embedded to this thesis. Abbreviations of Table 2 are
explained in the footnote of the table. 
Table 2. Summary of materials and methods
Study Materials and Methods Publication
Liposome preparation and 
surface coating 
Thin film hydration and sequential extrusion 
by syringe mini extruder, Avanti Polar Lipids
I, II, III, IV, 
UR
DSPE-HA was synthesized using reductive 
amination of 8-15 kDa HA sodium salt. The 
conjugated lipid was used for liposome 
preparation with thin film hydration and 
extrusion. 
II






Ramucirumab (Cyramza®) fragmentation into 
F(ab’)2 using immobilized pepsin digestion, 
Pierce™. F(ab’)2 purification with 50 kDa 
Pur-A-Lyzer™ dialysis membrane
UR
Thiolated Fab’ fragment was obtained by 
reducing the F(ab’)2 with 2-
mercaptoethylamine hydrochloride (2-MEA) 
and purified with gel filtration (Superdex®
200)
UR
Anti-VEGFR-2 Fab’ fragment conjugation of 
liposomes using click chemistry between 
maleimide-PEG-PE and thiolated Fab’ 
fragment
UR
Targeted liposome purification from free Fab’ 
fragments with Sepharose® CL-2B 
UR
Liposome characterization Particle size analysis with dynamic light 
scattering (Zetasizer APS, Malvern 
Instruments)
I, II, III, IV, 
UR
Particle size analysis in vitreous and plasma 




Surface charge (zeta potential) measurement 
by electro-kinetic analysis, Zetasizer ZS and 
DTS1070 cuvette (Malvern Instruments)
I, II, III, IV, 
UR
Lipid phase transition analysis by DSC, 
Mettler Toledo
II
DSPE-HA conjugation analysis by FTIR 
spectrometer and 1H-NMR, Bruker
II
Antibody fragmentation validation by non-
reducing SDS-PAGE, BioRad™
UR
Fab’ fragment conjugation analysis by single 
particle automated Raman trapping analysis 
(SPARTA™)
Binding affinity to VEGFR-2 (recombinant 
human His-tagged protein, SinoBiological 





Sunitinib quantification and stability analysis 
(at 4 °C and 37 °C) by UPLC with a gradient 
method, Waters 
IV
Formation and characterization of sunitinib-
cyclodextrin (hydroxypropyl β-cyclodextrin) 
inclusion complex using phase solubility 
method
IV
Liposome stability and 
drug release
ICG stability assay by light absorbance 
measurement through spectroscopy 
II
Passive leakage stability assay by calcein 
fluorescence analysis at 35-37 °C (during one 
week), Varioskan LUX
II
Light-triggered release assay by calcein 
fluorescence analysis (Varioskan LUX) after 
light induction with single-mode laser module 
(ML6700, Modulight Inc.)
II
Suninitib release study from liposomal 
formulation by rapid equilibrium dialysis, 
(RED device, 8 kDa cut-off), analysis by 




Porcine vitreous preparation by vitreous 
extraction, homogenization and filtration
I, II





Vitreal mobility study Visualization of particles’ diffusion in intact 
porcine vitreous within the eyecup using 
confocal microscopy, 3i Marianas and 
Slidebook 6 software
I, II
Single particle tracking (SPT) by Imaris 9.2 
software and calculation of mean square 
displacement (MSD) by @MSDanayzer 
MATLAB plugin 
I, II
Protein corona structure 
and composition 
Surface plasmon resonance measurement by 
MP-SPR Navi™ 200, Bionavis 
I, II
Proteomics sample preparation using in-
solution tryptic digestion protocol for both 
plasma and vitreous
I, II
Determination of protein concentration by 
BCA protein assay 
I, II
Proteomics data acquisition by LC-MS/MS, 
Orbitrap Fusion Instrument 
I, II
Spectral sequencing, protein groups 
identification and quantification in hard and 
soft corona with MaxQuant v.1.0.1.6 
I, II
Proteomics data analysis with principal 
component analysis (PCA), differential 
abundance and hierarchical clustering, 
Perseus software v. 1.5.6.0
I, II
Computing grand average of hydropathy 
(GRAVY) and theoretical isoelectric point 
(PI) for enriched proteins in the corona by 
ExPASy ProtParam tool 
I, II
Additional data analysis and statistics were 
conducted using GeneMANIA, Venn software 
and GraphPad Prism
I, II
Protein corona thickness measurement by 
modified Jung model, Spreadsheet software
I, II
Ex vivo retinal penetration 
study 
Preparation of bovine retinal explants (with 
and without vitreous) and culturing on 
Transwell® nourished by supplemented 
Neurobasal® A-medium
III
Retinal explant exposure to liposomes through 
direct application on top of the retina or 
intravitreal injection using 30 G needle
III
Tissue snap freezing using dry ice following 




Cryo-sectioning from different retinal explant 
sites with Cryostat, Leica CM3050s
III
Immunohistochemistry using rabbit anti-
collagen IV antibody (1:200), Alexa Fluor™ 
488-tagged goat anti-rabbit secondary 
antibody (1:500) and Hoechst (1:1000), 
Invitrogen
III
Visualization and imaging performed with a 




Preparation of laser-induced choroidal 
neovascularization mouse model by retinal 
photocoagulation laser, Vitra2 Quantal 
Medical
IV
Formation and development of CNV was 
monitored using optical coherence 
tomography (OCT) and fluorescein fundus 
angiography (FA) (Micron IV; Phoenix 
Research Labs
IV
Comparative analysis of the leakage area 
following the animal treatment using 
angiograms
IV
Additional analysis Image analysis and statistical analysis by FIJI, 
ImageJ 1.51 and GraphPad Prism 8.2.1
III, IV
HA, hyaluronic acid; DSPE, 1,2-distearoyl-sn-glycero-3-phosphorylethanolamine; ICG,
indocyanine green; SEC, size exclusion chromatography; VEGFR-2, vascular endothelial 
growth factor receptor-2; LALS, large angle light scattering; DSC, differential scanning 
calorimetry; FTIR, Fourier-transform infrared spectroscopy; 1H-NMR, proton nuclear 
magnetic resonance; SDS-PAGE, sodium dodecyl sulphate–polyacrylamide gel 
electrophoresis; UPLC, ultra-performance liquid chromatography; BCA, bicinchoninic 
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10   DISCUSSION
Intravitreal VEGF-neutralizing biologics are the main treatment for the retinal and 
choroidal diseases (e.g. AMD and DR). However, it is now known that other mechanisms 
are also involved in the pathogenesis of these diseases, including inflammation and 
neurodegeneration that are not responsive to anti-VEGF therapy [118]. Small molecule 
drugs show promise in the retinal and choroidal treatment [5,57], but their elimination 
from the vitreous is fast (half-lives 1-10 hours), resulting in poor clinical utility as 
intravitreal solutions [4,80]. Therefore, prolongation of vitreal drug retention and sustained 
release are required formulation properties. In this respect, one approach is to employ 
nanotechnology-based drug delivery systems for prolonged retention in the eye. Despite all 
efforts, retinal drug delivery is still challenging due to the complex ocular barriers. This 
thesis provides information on the fundamentals that must be considered in the design of 
retinal drug delivery systems based on lipid-based nanoparticles. In the following sections, 
the methods and results of this study are discussed. 
10.1. Mobility of lipid-based nanoparticles in the vitreous
The vitreous humor is the first barrier that nanoparticles encounter upon IVT injection. The 
interaction of nanoparticles with the vitreous may have influence on their ocular 
pharmacokinetics. Publication I and II involved characterization of nanoparticles in 
physiological environment and evaluation of nanoparticle diffusion in the vitreous. 
Rodents have impaired translational value due to the significant anatomical differences 
compared to the human eye. Therefore, this study was based on ex vivo investigations of 
intact porcine vitreous. Mobility of nanoparticles was analysed using a modified procedure 
based on the report of Xu and colleagues [206]. The relevance of animal model is of great 
importance, since the size of the eye (vitreous volume) and the vitreous structure can affect 
the nanoparticle mobility. In this experimental system, the anterior segment of the porcine
eye was removed, exposing the intact vitreous. Diffusion of labelled nanoparticles were 
followed after IVT injections into the centre of vitreous gel. The average anteroposterior 
axis in porcine eye (23.9 mm) is similar with the human eye (24 mm) [242]. Furthermore, 
the viscoelastic properties of central porcine vitreous are similar to human vitreous [243-
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246], whereas bovine vitreous has higher viscosity [245,247]. Also, the concentration of 
HA in the central porcine vitreous and human vitreous are similar; important factor for the 
the electrostatic interactions between vitreous and nanoparticles [248]. This improved our 
confidence on the translational value of our ex vivo model, even though most of earlier 
studies on vitreal mobility have utilized bovine vitreous [206,207].
Single particle tracking was applied in this study allowing determination of the mean 
square displacement and diffusion coefficients of labelled IVT nanoparticles [206,207].
Single particle tracking allows live tracking of nanoparticles at high temporal and spatial 
resolution [249].  This method has been used in colloidal studies and biophysics and it 
enables discrimination between random diffusion, convection and obstructed movements 
in the matrix [249,250]. Such analyses provide valuable information regarding the extent 
of vitreous impediment to nanoparticles’ movement. Furthermore, it informs about the 
influence of nanoparticle properties on vitreal mobility. Therefore, we compared the vitreal 
mobility of 36 IVT liposomal formulations with different sizes, surface coatings and 
charges. Also other lipid-based nanoparticles, such as hexosomes and NLCs, were assessed 
with the same method.
Overall, our work shows that neutral and negatively charged lipid-based nanoparticles (< 
200 nm) are relatively freely mobile in the vitreous (Fig. 2, publication I), but the vitreous 
severely obstructs diffusion of the cationic formulations regardless of their size. This 
highlights the significant role of surface charge in the mobility of nanoparticles in the 
vitreous. In terms of surface coating, we observed that the effect of surface coating is more 
prominent in less mobile nanoparticles (e.g. cationic liposomes), while it showed marginal 
to moderate impact on the diffusion of anionic and neutral particles.  Presumably, PEG and 
HA can mask the cationic charges on the liposomal surface to some extent thereby 
reducing the electrostatic interactions, but the diffusion was still more restricted than in the 
case of anionic and neutral liposomes. 
Interestingly, the data shows that PEG-coated liposomes diffuse faster than the HA-coated 
liposomes.  Steric shielding of PEG seems to interact less than HA with the vitreous (Fig. 
10, publication II). Hence, negative charges (HA) do not necessarily improve the vitreal 
mobility over neutral coating (PEG) suggesting that the interplay with the vitreous is 
complex and involves many mechanisms. Furthermore, the high-resolution proteomics 
study confirmed that the HA-coated liposomes interact with structural collagen meshwork 
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that may render them less mobile (publication II). This feature may be employed to extend 
the vitreal half-life by HA-conjugation. For instance, HA-conjugated sFlt-1 (soluble VEGF 
decoy receptor) had 10-fold longer vitreal half-life than the unconjugated sFlt-1 [251].
Although, the authors linked this behaviour to the increased molecular size, one should 
note that the interaction of HA with the vitreal components may also contribute to 
improved ocular retention. Similarly, ocular retention and duration of action of IVT 
nanoparticles might be improved by HA coating. Huang et al. reported prolonged retinal 
effect in rat model after coating Cx43-mimetic peptide containing human serum albumin 
with HA  [252]. Herein, the HA was applied to target the CD44-receptor expressing retinal 
cells, but the extended vitreal retention can be related to HA-collagen interactions.
Our data and calculations suggest that the vitreal distribution of nanoparticles in vivo is 
probably controlled by convection in healthy young vitreous, but it may shift toward 
diffusion-control with aging as the vitreous undergo liquefaction (Table 3, publication I).
On the contrary, the effect of vitreal liquefaction on the mobility of antibodies is 
inconsequential, since their transport is mostly governed by diffusion. The vitreal mobility 
behaviour in the vitreous substitutes, however, remains elusive, because the velocity of 
convective flow and stability of nanoparticles in vitrectomized eyes are not known. 
Furthermore, it seems that in small rodent eyes diffusion is always the major controlling 
factor in the IVT distribution of drugs and nanoparticles.
Moreover, pharmacokinetics of liposomes and other nanoparticles may be influenced by
formation of biocorona or protein corona on their surface. Thus, the characteristics of 
nanoparticles may change after their exposure to the vitreous [253]. This biological 
identity may shape cell level pharmacological properties of the nanoparticles as well as 
their vitreal mobility. Although, the importance of protein corona has been recognized in 
nanomedicine [253,254], the vitreal corona of liposomes has not been previously explored 
[255,256]. Protein interactions may also affect drug release behaviour and cellular uptake 
of liposomes [257]. Therefore, we explored the protein corona formation on the liposomes 
in the presence of porcine vitreous using recently established work flow that involves 
sequential surface plasmon resonance and mass spectrometry analyses of the protein 
coronas. We explored uncoated, PEGylated and HA-coated light activated liposomes 
(Table 4, publication II). The extent of protein corona formation was comparable between 
anionic PEGylated (50 nm) and uncoated liposomes indicating that the PEGylation did not 
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attract more vitreal proteins. Even though protein corona increased the liposome size by 
10-12%, it is likely that their vitreal mobility was not significantly affected. The same 
conclusion is applicable also to HA-coated liposomes, even though they bound more 
protein than the PEG-coated liposomes. In addition, our observations suggest that the 
anionic liposomes retain their negative charge in the vitreous irrespective of their coating, 
since the twenty most abundant proteins in the liposomal protein coronas were
predominately negatively charged (Fig. 7, publication II). Hence, it is evident that protein 
corona does not mask the negative surface charge of the liposomes. 
The comprehensive analysis of protein properties revealed the presence of immune system 
components (e.g. complement C3, clusterin, apolipoprotein E) in the protein corona of 
anionic and neutral liposomes implying that the opsonisation may be involved in the ocular 
elimination process.
Nonetheless, further work is required to elucidate the impact of protein corona on ocular 
biodistribution of liposomes in healthy and diseased eyes. The findings build improved
understanding of the barriers in retinal drug delivery.
10.2 Retinal penetration of liposomes across the vitreoretinal interface
In publication I and II, we demonstrated the key factors affecting the mobility of 
liposomes in the vitreous. However, in many cases liposomes must distribute to the retina 
to deliver their cargoes into the retinal cells in order to exert actions of RNA, DNA or 
intracellularly acting peptides in the cells. Therefore, after successful distribution within 
the vitreous, the liposomes should permeate into the retina across the vitreoretinal barrier 
(in particular, ILM). Therefore, we explored retinal permeation of anionic and neutral 
liposomes with good vitreal mobility. Moreover, we studied the effects of PEG coating, 
surface charge, and size of liposomes on retinal penetration (publication III).
There are many published reports on effective retinal drug delivery with nanoparticles, but 
the experiments were performed in murine in vivo or ex vivo models [210,211,258]. As 
discussed above, ocular barriers are different in small laboratory animals compared to 
larger species and humans. Thus, we used bovine retinal explants to obtain relevant 
information about ILM barrier. The thickness of bovine ILM is comparable to the human
ILM, whereas the rodents have simpler and thinner ILM structure that is more similar to 
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the human foetus (ILM thickness ≈ 0.07 μm) [87,88]. In addition, the ILM undergoes age-
related changes leading to thicker and stiffer structure [86]. These facts highlight the 
importance of relevant models. Herein, two different retinal explants were used: without 
vitreous (R-explant) and with attached vitreous (VR-explant). The latter model simulates 
the structure of vitreoretinal interface and allows to explore the role of the intact ILM, but 
the VR-explant preparation is more laborious than the R-explant. Therefore, we first 
evaluated the penetration of liposomes in the R-explant and, later, selected cases in VR-
explant.
In R-explant, the eyecup was cut to have 4 flaps, optic nerve being in one of the flaps, but 
the optic nerve region was avoided in the experiments due to its different structure [11].
The other three flaps were punched using similar distances from the centre of the eyecup
and treated with optimized volume of liposomes (10 μl) ensuring that the formulation 
covers the explant but without over-spilling to the edges of the explants. In VR-explant, the 
liposomes were injected IVT in the centre of explant (Fig. S1, publication III) and the 
needle was taken out of the vitreous after few seconds to avoid spillage of liposomes due to 
backpressure. We also made sure not to take any microscopic images at the edges of the 
retinal sections. With such considerations, we minimized the risk of misleading results due 
to any edge contact of the liposomes.
Overall, the small anionic liposomes (< 50 nm) with PEG showed the best retinal 
distribution. The semi-quantitative analysis helped us to highlight the impact of surface 
charge in retinal entry. According to Figure 2C (publication III), the number of sections 
with more than 42 particles (data above 75th percentile) inside the retinal layers was higher 
for anionic liposomes than for neutral ones. Presumably, the anionic liposomes have lower 
interactions than neutral liposomes both with vitreous and ILM. In addition, the Müller 
cells may affect retinal penetration due to their interactions with anionic particles as they 
are phagocytic cell type [216]. In terms of surface coating, PEG displayed positive impact 
on liposomal permeation across the vitreoretinal barrier. This was seen as more consistent 
retinal penetration of PEGylated liposomes as compared to uncoated ones. Even though 
there are sparse data about influence of PEG on retinal permeation, a recent study reported 
that PEGylation with a molecular weight of ≥ 2000 Da improves the nanoparticle transport 
across ocular mucosal barriers [259]. This can also be leveraged to explain higher retinal 
entry of PEG-coated liposomes, because the structural components of vitreous and ILM are 
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relatively similar with the mucus. Interestingly, co-localization of liposomes with retinal 
ganglion cells (RGC) was observed, implying potential application of the localization for 
targeting RGC to treat retinal degeneration in glaucoma [39,52] (Fig. 1, publication III).
In addition to surface charge and surface coating, retinal permeation is also influenced by 
particle size as larger liposomes (≈100 nm) failed to cross the vitreoretinal barrier. This 
suggests that the sieve-like structure of ILM does not allow particles of over 100 nm to 
enter retinal layers. Nonetheless, breached ILM displayed leakier barrier in which larger 
liposomes distributed in retinal layers (Fig. S3, publication III). Similarly, in certain 
diseases, such as proliferative diabetic retinopathy, the ILM may become compromised
potentially leading to higher retinal permeation, but the leakiness is often associated with 
late-stage of disease [260]. The relation between retinal distribution and disease state is 
complex and it is more meaningful to study the barrier role firstly in the intact ILM. This 
would help to design a drug delivery system that permeate into the retina even through the 
uncompromised vitreoretinal interface.
Our data extends understanding of the retinal barriers, which is important in the design of 
drug and gene delivery systems for retinal therapy. Indeed, retinal barriers determine the 
route of administration, for instance, subretinal injection can be considered the most 
effective method for delivering of viral vectors since their permeation from vitreous into 
the retina is challenging. Nonetheless, problems in understanding the barriers and use of 
rodents in the preclinical studies have generated over-optimistic expectations, partly 
explaining the lack of IVT nanoparticles and viral vectors in the clinical use. 
10.3 Liposomal sunitinib for treatment of choroidal neovascularization
Study IV involved development of sunitinib-loaded liposomes for treatment of choroidal 
neovascularization (CNV). Sunitinib maleate has received FDA approval for oral 
administration in the treatment of renal cell carcinoma [261,262]. It is a tyrosine kinase
inhibitor which blocks all VEGFRs as well as PDGFR leading to suppression of the VEGF 
expression in newly formed choroidal vessels [5,140,142,263-265]. Thus, it is an 
alternative approach to anti-VEGF biologics for blocking the VEGF signalling pathway 
associated with ocular neovascularization. In addition to the ocular neovascularization, 
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sunitinib may be useful in ocular diseases characterized with retinal degeneration (such as 
glaucoma and dry-AMD) owing to its neuroprotective properties [137].
Considering the dose-dependent toxicity of sunitinib and the rapid intravitreal elimination 
of small molecules, a drug delivery system is required for intraocular administration of 
sunitinib [4,57]. With this potential in mind, we developed anionic PEGylated (≈ 100 nm) 
liposomes through thin film hydration method for solubilizing the sunitinib as IVT 
injectable formulation. Liposomal formulations are biocompatible and biodegradable, and 
they have been accepted for clinical use as eye drops and intravenous injections [266,267].
For example, Visudyne® is an intravenous liposomal photodynamic therapy product for 
CNV treatment [8]. IVT formulation would avoid the systemic toxicity of sunitinib by low 
dose and limiting drug release to the intraocular space. 
Anionic liposomes with PEG coating are capable to overcome relevant ocular barriers, as 
discussed in previous sections. Hence, lipid composition was selected accordingly, 
including DSPG and PEG-DSPE in the formulation. Unlike light-activated liposome 
formulation, in which lower phase transition temperature was desired, we substituted the 
single hydrocarbon chain phospholipid (Lyso-PC) and short length hydrocarbon chain 
phospholipid (DPPC) with DSPC and DOPC. Such a composition avoids lipid bilayer 
leakiness while it provides sufficient firmness to prolong the drug release for a few days 
(Fig. 2, IV). In this study, we used sunitinib as lipophilic free base form to maximize 
encapsulation and optimize drug release. In this regard, sunitinib was encapsulated in the 
lipid bilayer by passive loading method that resulted in 95 % encapsulation efficiency. 
Also, liposomal sunitinib revealed relatively high loading capacity (≈ 5 %) allowing 
intravitreal dosing of at least 1 μg per 1 μl of injection [268]. Although encapsulation of 
sunitinib results in promising encapsulation efficiency, evaluation of its release profile 
from liposomes was challenging, because it has poor water-solubility. We addressed the 
solubility issue by introducing cyclodextrin to the receiver chamber of equilibrium dialysis 
device. In this respect, the solubility of sunitinib in PBS was improved up to 150-fold
when hydroxypropyl β-cyclodextrin was complexed with sunitinib at 24:1 molar ratio. 
Herein, excess amount of hydroxypropyl β-cyclodextrin, a FDA-approved excipient for 
ophthalmic preparations, was employed to form inclusion complexes with sunitinib (Fig. 1, 
IV) thereby providing sink conditions for drug release. 
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The formulation was studied first for endotoxin with Limulus Amoebocyte Lysate (LAL) 
assay, which confirmed the non-pyrogenic injection material. The CNV mice received 1 μl 
of IVT liposomal sunitinib. It was evident from our fluorescein angiograms that liposomal 
sunitinib effectively prevented the vascular leakage for 3 days, presumably by reducing 
drug elimination from the vitreous while sunitinib-cyclodextrin solution did not show any 
anti-neovascular effect. Furthermore, evidence indicates that the ocular pharmacokinetics
of sunitinib can be influenced by its binding to melanin in pigmented tissues, such as iris, 
ciliary body, RPE and choroid [269]. In such conditions, the drug-melanin complex may 
lead to reduced concentration of free drug, possibly reducing the peak pharmacological 
response [270]. Nevertheless, melanin complex may also serve as a drug depot thus 
extending the half-life of drug in the posterior segment of the eye [271]. Moreover, the 
retention time is generally longer when we translate it to human eye owing to its larger 
volume of the vitreous (4 ml) compared to mouse model (5 μl). 
Overall, sunitinib offers promising therapeutic option for treatment of nvAMD owing to its 
dual role of being neuroprotective and anti-neovascular compound. Previously, we 
discussed about the survival role of sunitinib for retinal ganglion cells by inhibition of dual 
leucine zipper kinase [137]. Although the mechanism of sunitinib protection of the 
photoreceptors is not yet known, Tsujinaka and colleagues observed thickening of the 
outer nuclear layer with sunitinib therapy in CNV mice, suggesting that sunitinib is 
involved in photoreceptor survival [264]. Therefore, sunitinib may pose an advantage over 
current anti-VEGF biologics in treatment of nvAMD. In this regards, Grunwald and 
colleagues revealed that long-term monthly injection of ranibizumab is a risk factor for 
photoreceptor cell death as 18% of patients on ranibizumab treatment developed GA after 
2 years [272].
10.4 Future prospects
In this work, we demonstrated that multiple factors are involved in successful retinal drug 
delivery with liposomes. However, many other aspects have yet to be studied regarding the 
correlation between liposome properties and their efficacy in circumventing ocular 
barriers. Herein, we applied healthy juvenile vitreous for diffusion study of lipid-based 
nanoparticles, but additional work is required to study their diffusion in diseased state 
models with more liquid vitreous, vitrectomized eyes and vitreous substitutes (e.g. silicon 
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oil and polymeric hydrogels) to assess behavior of liposomes in those conditions. Even 
though there are some reports on vitreal clearance of anti-VEGF drugs (ranibizumab and 
aflibercept) in vitrectomized non-human primates such as macaque eyes [273,274], the
knowledge about the effect of vitrectomy on vitreal distribution of particulate formulations 
is limited. Therefore, further investigation is needed to understand the factors that affect 
vitreal mobility (diffusion and convection) in various conditions. Certainly, improved tools 
and understanding are needed for inter-species translation of in vivo data to the humans
[275,276].
The protein binding interactions may also be influenced in diseased eyes, thus it would be 
useful to explore the protein corona enrichment using a diseased vitreous involving 
diabetic changes [277]. In this case, the vitreal proteins may be different, potentially 
affecting ocular pharmacokinetics of liposomes. Furthermore, the impact of different 
protein classes on immune response, safety and cellular interactions of liposomes requires 
further exploration.
Herein, the fundamentals for efficient transport of nanoparticles from the site of intravitreal 
injection toward retina were presented, nonetheless another way to leverage these 
information would be to develop less mobile formulations for prolonged ocular retention 
and sustained drug release. This can be achieved, for instance, by HA-modification of 
liposomes to increase the interactions with collagen network, although optimization of the 
HA coating parameters is still needed. Alternatively, increasing the size of nanoparticles 
above the mesh size of vitreous meshwork (> 550 nm) may provide extended therapeutic 
concentrations, if drug release will be slow enough and adequate drug loading can be 
accomplished. Such approach could be combined with melanin-binding drugs, such as 
sunitinib, to generate a secondary depot in pigmented eye tissues for further prolongation 
of drug effects. GB-102 formulation (sunitinib loaded polymeric-based microparticles) is 
an example of this strategy, and is currently in clinical trials for wet-AMD with twice-
yearly dosing regimen [140].
Our findings confirmed that removal of the vitreous, common procedure in conventional 
explant studies, and use of mice retina have led to overestimation of nanoparticles’ retinal 
distribution. We presented a bovine vitreoretinal explant model that is more representative 
for human situation.  The model is in line with three R principles, allowing simultaneously 
investigating nanoparticle interactions with vitreous and ILM, the main barriers in retinal 
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drug delivery. Nonetheless, this model could be improved by dynamic circulation of 
culture medium in flow systems (e.g. Quasi-vivo®).
As discussed earlier, physicochemical characteristics of lipid-based nanoparticles influence
their retinal permeation. Numerous biological factors, including age, disease and cellular 
activity, may be involved in retinal distribution, but are still unknown. In addition 
localization of small anionic PEGylated liposomes was observed in ganglion cell layers, it 
is therefore of great interest to explore the potential of such formulations for the delivery of 
neuroprotective compounds for treatment of retinal neurodegenerative conditions, such as 
glaucoma. Interestingly, we have observed that the shape (tubular vs spherical) of 
polymeric nanostructure seems to affect their ability to pass vitreoretinal interface [278],
but more detailed studies are still needed.
Drug treatment may be affected by cellular resistance mechanisms, such as influx and 
efflux transport [279]. For instance, sunitinib is a substrate for P-glycoprotein transport in 
the RPE cells. Interestingly, nanosystems may bypass efflux transport within the cells, thus 
improving drug efficacy. Taken together, although the anti-VEGF injections revolutionized 
the treatment of retinal diseases, such as AMD, further improvements are needed to enable 
use of intracellular biologics (e,g RNA) in retinal therapy, to prolong the injection intervals 
of intravitreal drugs and targeting drugs to the retinal and choroidal cells.  
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11   CONCLUSIONS
This thesis is focused on the properties of lipid-based nanoparticles, such as liposomes, as 
retinal drug delivery systems. The following specific conclusions were reached. 
1. Surface charge of nanoparticles has significant impact on their vitreal mobility, 
cationic particles showing much lower mobility than the anionic and neutral ones. 
Increasing size of the lipid-based nanoparticles (from < 50 nm up to 200 nm) has 
modest slowing effect of mobility when the particle size was smaller than pore size 
of the vitreous meshwork.
2. PEG-coating improves the vitreal diffusion of liposomes, particularly in the case of 
slowly diffusing cationic liposomes. 
3. HA-coated liposomes have lower vitreal mobility than PEGylated counterparts due 
to their interactions with vitreal components.
4. IVT distribution of nanoparticles is dominated by convection in large eyes, whereas 
antibody distribution is diffusion-dependent. In rodent eyes, vitreal distribution is 
ruled by diffusion. 
5. Protein corona formation after exposure to porcine vitreous affects liposomes size 
only minimally, thereby not affecting their mobility in the vitreous. Liposome 
coating with PEG or HA do not result in further protein enrichment.
6. Vitreoretinal interface in bovine retinal explants is a significant barrier for retinal 
penetration of liposomes and serves as valuable model for retina permeation 
studies. 
7. Liposomes over 100 nm fail to overcome vitreoretinal interface barrier, while small 
liposomes below 50 nm in diameter do permeate to the retina.
8. Negative surface charge and PEG-coating facilitate the retinal permeation of 
liposomes.
9. Liposomes are capable of localization to the retinal ganglion cells.
10. Anionic PEGylated liposomes efficiently encapsulate sunitinib and showed anti-
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